Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment Type
3.2. Snippet by Disease Indication
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising awareness among women
4.1.2. Restraints
4.1.2.1. High Costs Associated with Women’s Medicine
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs

6. By Treatment Type
6.1. Introduction
6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Hormonal Therapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Estrogen Therapy
6.2.4. Progesterone Therapy
6.2.5. Combination Therapy
6.2.6. Thyroid Replacement Therapy
6.2.7. Others
6.3. Bone Health Agents
6.4. Pain and Symptom Management Agents
6.5. Metabolic Agents
6.6. Nutrition Supplements
6.7. Others
7. By Disease Indication
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
7.1.2. Market Attractiveness Index, By Disease Indication
7.2. Thyroid Disorders*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Gynecological Disorders
7.3.1. PMS
7.3.2. PCOD
7.3.3. Uterine Fibroids
7.3.4. Endometriosis
7.3.5. Others
7.4. Cancer
7.5. Bone Disorders
7.6. Others
8. By Region
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.5.1. U.S.
8.2.5.2. Canada
8.2.5.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.5.1. Germany
8.3.5.2. U.K.
8.3.5.3. France
8.3.5.4. Spain
8.3.5.5. Italy
8.3.5.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.5.1. Brazil
8.4.5.2. Argentina
8.4.5.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.5.1. China
8.5.5.2. India
8.5.5.3. Japan
8.5.5.4. South Korea
8.5.5.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
9. Competitive Landscape
9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis
10. Company Profiles
Key Market Players
10.1. Bayer AG*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue’s
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals etc.
10.1.5. SWOT Analysis
10.2. Agile Therapeutics
10.3. Amgen Inc.
10.4. Lupin
10.5. Sandoz AG
10.6. Otsuka Pharmaceutical Co., Ltd.
10.7. Nestl?.
10.8. Radius Health
10.9. Eli Lilly and Company
10.10. Seed Health
* Similar data will be provided for each market player.
Emerging Market Players
10.11. AbbVie Inc.*
10.11.1. Pipeline Products Description
10.11.2. Product Key Performance Indicators (KPIs)
10.11.3. Key Activities
10.11.4. Market Entry Timelines
10.11.5. Product Penetration Rate
10.11.6. Sales Estimation and Projections
10.12. Pfizer, Inc.
10.13. Theramex
10.14. Blairex Laboratories, Inc.
10.15. Ferring
10.16. Vitabiotics India
* Similar data will be provided for each market player.
LIST NOT EXHAUSTIVE
11. Appendix
11.1. About Us and Services
11.2. Contact Us